eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank


 
3/2010
vol. 9
 
Share:
Share:
more
 
 
abstract:
Review paper

Endocrinology of aging males

Michał Rabijewski, Wojciech Zgliczyński

Przegląd Menopauzalny 2010; 3: 184–189
Online publish date: 2010/06/16
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Aging in men is accompanied by gradual decline of all physiological functions, involving the heart, lungs, kidneys, liver and brain as well as the endocrine systems. The symptomatology is characterized by a decrease in general well-being, work capacity, muscle mass and strength, virility, sexual pilosity, libido and sexual activity, by a greatly increased frequency of impotence, increased body fat, osteopenia and atherosclerosis, and a decline in cognitive performance, forgetfulness and sleep disturbances. Many of these symptoms are reminiscent of symptoms of hormone deficiency such as hypogonadism, growth hormone (GH), deficiency or hypothyroidism, although it often remains difficult to evaluate the relative contribution of the aging process itself, the endocrine alterations or the permanent consequences of previous diseases to the symptomatology in aging males. We present here some reflections on the involvement of the endocrine system in the aging process in men.
keywords:

testosterone, growth hormone, melatonin, DHEA, diabetes, thyroid, aging

references:

United Nations Department for Economic and Social Information and Policy Analysis, Population Division. World Population Prospects: The 2004 revision. New York United Nations, 2004.

Vermeulen A. Some reflections on the endocrinology of the aging male. The Aging Male 1998; 1: 163-8.

Nieschlag E, Swerdloff R, Behre HM, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. THe Aging Male 2009; 12: 5-12.

Vermeulen A, Kaufman JM Aging of the hypothalamo-pituitary-testicular axis in men. Horm Res 1995; 43: 25.
Snyder P. Effects of age on testicular function and consequences of testosterone treatment. J Clin Endocrinol Metab 2001; 86: 2369-72.

Feldman HA, Longcope C, Derby C, et al. Age trends in the level of serum testosterone and other hormnes in middle-aged men: longitudinal results from Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002; 87: 589-8.

Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at 45 years; the HIM Study. Int J Clin Prac 2006; 60: 762-9.

Araujo AB, O’Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older man: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920-6.
Rabijewski M, Jakiel G, Zgliczyński W. Zespół niedoboru testosteronu. Medycyna po Dyplomie 2008; 7: 77-9.
Kalyani RR, Dobs AS. Androgen deficiency, diabetes and metabolic syndrome. Curr Opin Endocrinol Obes 2007; 14: 226-34.

Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234-8.

Muller M, Grobbee DE, den Tonkelaar I, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-23.

Muller M, YT van der Schouw, Thijssen JHH et al. Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 2003; 99: 5076-86

. Shores MM. Matsumoto AM, Sloan KL, et al. Low testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660-5.

Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3578-83.

Yassin AA, Saad F. Improvement of sexual functions in men with late-onset hypogoonadism treated with testosterone only. J Sex Med 2007; 4: 20-8.

Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407-13.

Snyder PJ, Peachey TW, Hannoush P, et al. Effects of testosterone treatment on body composition and muscle strength in men over 65 years old. J Clin Endocrinol Metab 1999; 84: 2647-53.

Snyder PJ, Peachey TW, Hannoush P, et al. Effects of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966-72.

Rabijewski M, Kubuj M, Zgliczyński S. Skuteczność i bezpieczeństwo hormonalnego leczenia zastępczego (HLZ) testosteronem u starszych mężczyzn z hipogonadyzmem. Endokrynol Pol 2003; 3: 293-300.

Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 1996; 81: 3147-51.

Allolio B, Arlt W. DHEA treatment: myth or reality. Trends Endocrinol Metab 2002; 13: 288-94.

Kroboth PD, Salek FS, Pittenger AL, et al. DHEA and DHEA-S: a review. J Clin Pharmacol 1999; 39: 327-48.
Labrie F, Belanger A, Simard J, et al. DHEA and peripheral androgen and estrogen formation: intracrinology. Ann NY Acad Sci 1995; 774: 16-28.

Dharia S, Parker CR, Jr. Adrenal androgens and aging. Semin Reprod Med 2004; 22: 361-368.

Yen SS. Dehydroepiandrosterone sulfate and longevity: new clues for an old friend. Proc Natl Acad Sci U S A 2001; 98: 8167-9.

Belanger A, Candas B, Dupont A, et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 1994; 79: 1086-90.

Baulieu EE. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology 1998; 23: 963-87.

Nawata H, Yanase T, Goto K, et al. Mechanisms of action of anti-aging DHEA-S and the replacement of DHEA-S. Mech Ageing Dev 2002; 123: 1101-6.

Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360-7.

Percheron G, Hogrel JY, Denot-Ledunois S, et al. Effects of 1-year oral administration of dehydroepiandrosterone to 60- to 80-yearold individuals on muscle function and cross-sectional area: a double blind placebo-controlled trial. Arch Intern Med 2003; 163: 720-7.

Hinson JP, Brooke A, Raven PW. Therapeutic uses of DHEA; a review. Curr Opinion Invest Drugs 2003; 4: 1205-8.

O’Connor KG, Tobin JD, Harman SM, et al. Serum levels of insulin-like growth factor-I are related to age and not to body composition in healthy women and men. J Gerontol A Biol Sci Med Sci 1998; 53: M176-M182.

Toogood AA, O’Neill PA, Shalet SM. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 1996; 81: 460-5.

Hull KL, Harvey S. Growth hormone therapy and quality of life: possibilities, pitfalls and mechanisms. J Endocrinol 2003; 179: 311-33.

Vance ML. Can growth hormone prevent aging? N Engl J Med 2003; 348: 779-80.

Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6.

Blackman MR, Sorkin JD, Minzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men. A randomized controlled trial. JAMA 2002; 288: 2282-92.

Perls TH, Reisman NR, Olshansky SJ. Provision or distribution of growth hormone for?antiagingî. Clinical and legal issues. JAMA 2005; 294: 2086-90.

Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Int Med 2007; 146: 104-15.

Karasek M. Melatonin, human ageing, and age-related diseases. Exp Gerontol 2004; 39: 1723-9.

Karasek M. Znaczenie kliniczne melatoniny. Postępy Nauk Medycznych 2007; 20: 395-8.

Pandi-Perumal SR, Seils LK, Kayumov L, et al. Senescence, sleep, and circadian rhythms. Aging Res Rev 2002; 1: 559-604.

Cardinali DP, Brusco LI, Perez Lloret S, et al. Melatonin in sleep disorders and jet-lag. Neuro Endocrinol Lett 2002; 23 (supl. 1): 9-13.

Skene D, Lockley SW, Arendt J. Use of melatonin in the treatment of phase shift and sleep disorders. Adv Exp Med Biol 1999; 467: 79-84.

Reiter RJ, Tan DX, Allegra M. Melatonin: reducing molecular pathology and dysfunction due to free radicals and associated reactants. Neuro Endocrinol Lett 2002; 23 (supl. 1): 3-8.

Reiter RJ, Tan DX, Osuna C, et al. Actions of melatonin in the reduction of oxidative stress. J Biomed Res 2000; 7: 444-58.

Maestroni GJM. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 2001; 10: 467-76.
Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem 2002; 2: 167-79.

Meneilly GS, Tessier D. Diabetes in the elderly. Diabetic Med 1995; 12: 949-60.

Oh JY, Barrett-Connor E, Wedic NM, et al. Endogenous sex hormones and the development of type 2 diabetes In older men and women, the Rancho Bernardo Study. Diabetes Care 2002; 25: 55-60.

Selvin E, Feinleb M, Hang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234-38.

Mariotti S, Franceschi C, Cossariazza A, et al. The aging thyroid. Endocr Rev 1995; 16: 686-715.

Rubisnstein HA, Butler VPJ, Werner SC. Progressive decrease in serum triiodothyronine concentrations with human radioimmunoassay following extration of serum. J Clin Endocrinol Metab 1973; 37: 247-53.

Mariotti S, Sansoni P, Barbesino G, et al. Thyroid and othewr organ specific autoantibodies in healthy centenarians. Lancet 1992; 339: 1506-8.

Viersinga WM. Subclinical hypothyroidism and hyperthyroidism. Prevalence and clinical relevance. Netherlands J Med 1995; 46: 197-203.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe